Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults

BACKGROUND: Merozoite surface protein 1(42) (MSP1(42)) is a leading blood stage malaria vaccine candidate. In order to induce immune responses that cover the major antigenic polymorphisms, FVO and 3D7 recombinant proteins of MSP1(42) were mixed (MSP1(42)-C1). To improve the level of antibody respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, Ruth D., Martin, Laura B., Shaffer, Donna, Long, Carole A., Miura, Kazutoyo, Fay, Michael P., Narum, David L., Zhu, Daming, Mullen, Gregory E. D., Mahanty, Siddhartha, Miller, Louis H., Durbin, Anna P.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809736/
https://www.ncbi.nlm.nih.gov/pubmed/20107498
http://dx.doi.org/10.1371/journal.pone.0008787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809736/
https://www.ncbi.nlm.nih.gov/pubmed/20107498
http://dx.doi.org/10.1371/journal.pone.0008787

Ejemplares similares